REGENXBIO
RGNX
Performance
About REGENXBIO
REGENXBIO is a leading clinical-stage biotechnology company focused on gene therapy. The company develops therapies using its NAV® Technology Platform to deliver one-time treatments for retinal, metabolic, and neurodegenerative diseases, aiming to improve lives for patients. Based in the United States, it emphasizes advancing novel AAV-based gene therapies through steady clinical programs and partnerships.
Recent News
4 Spaces Primed for the Next Wave of Gene Therapies
AI, Gene Therapies Drive Market Trends in Eye Care
Federal Circuit’s Holding on Patent Eligibility for Engineered Host Cells Dovetails With PERA
Makary Resigns, BMS Bets $15B on China R&D, and Regenxbio Wins Phase 3 in Duchenne – This Week in Biotech #100
Labiotech’s 15 Biopharma Companies to Watch in 2026
Biotech Insights - Spring 2026
FDA’s Accelerated Approval Messaging Collides with CRL Reality
Regenxbio's RGX-202 Hits Phase 3 Primary Endpoint, Eyes FDA Filing
REGENXBIO's RGX-202 Gene Therapy Hits Pivotal Efficacy Endpoint in Duchenne Trial
Early Intervention an Unmet Need in Diabetic Macular Edema
At Least Nine PDUFAs on FDA February Docket
Biopharma Catalysts in Q2 2026 Signal High-Profile Approval Decisions and Rising Competition
Regenxbio’s RGX-202 Gene Therapy Hits Primary Endpoint in Phase 3 Duchenne Trial
Sarepta Saga Has 'Gone on Too Long' As Competitors Catch Up
Published FDA Rejections Point to Manufacturing, Data Gaps as Key Stumbling Blocks
REGENXBIO Hit with Securities Fraud Class Action; Lead Plaintiff Deadline Set for April 14
FDA Reversals in Rare Disease Space Highlight Confusion Around External Controls
From Awareness to Acceleration: Rare Disease Drug Development Enters a Pivotal Era
JPM Day 3: Rare Disease in the Spotlight
Cassidy Names Areas of Improvement for FDA’s Regulatory ‘Black Box’
FDA Accepts BridgeBio’s Application for Potential First Limb-Girdle Muscular Dystrophy Drug
REGENXBIO Delay Could Put Denali in Pole Position for Hunter Syndrome Approval
Gene Therapy’s Evidence Problem—Lessons From Recent FDA Decisions
STAT+: FDA Rejects Regenxbio’s Rare-Disease Gene Therapy
The Slow March of Clinical Biomarkers to Become Surrogate Endpoints
Recent Deals
No recent deals for this company.